PNTG Pennant Group
Pennant Group earnings company data as of 12:00 PM ET 10/23
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 4 Nov | EPS | 0.28 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by PNTG's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $690K sold by 3 insiders under 10b5-1 plans
-
Jason Paul Steik Chief Clinical OfficerPlanned sale$54K 1,394 shares at $38.52 8.4% of stakeTraded Aug 6 Filed Aug 10
-
Brent Guerisoli CEOPlanned sale$165K 4,285 shares at $38.52 4.1% of stakeTraded Aug 6 Filed Aug 10
-
Kirk Sterling Cheney EVP, GC and Corp SecyPlanned sale$54K 1,393 shares at $38.52 7% of stakeTraded Aug 6 Filed Aug 10
-
Brent Guerisoli CEOPlanned sale$131K 3,159 shares at $41.57 3% of stakeTraded Jul 10 Filed Jul 14
-
Brent Guerisoli CEOPlanned sale$128K 3,165 shares at $40.51 3% of stakeTraded Jul 7 Filed Jul 9
-
Brent Guerisoli CEOPlanned sale$158K 4,508 shares at $35.08 4.4% of stakeTraded May 22 Filed May 27
Also filed in the last 12 months, not counted as buying or selling: 32 stock grants and 5 option exercises.
SEC filings
Recent issuer filings from EDGAR, 9 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.